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Abstract Microcystins, potent heptapeptide hepatotoxins pro-
duced by certain bloom-forming cyanobacteria, are strong pro-
tein phosphatase inhibitors. They covalently bind the serine/
threonine protein phosphatases 1 and 2A (PP1 and PP2A),
thereby in£uencing regulation of cellular protein phosphoryla-
tion. The paralytic shell¢sh poison, okadaic acid, is also a po-
tent inhibitor of these PPs. Inhibition of PP1 and PP2A has a
dualistic e¡ect on cells exposed to okadaic acid or microcystin-
LR, with both apoptosis and increased cellular proliferation
being reported. This review summarises the existing data on
the molecular e¡ects of microcystin-LR inhibition of PP1 and
PP2A both in vivo and in vitro, and where possible, compares
this to the action of okadaic acid.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Microcystin-LR (MCLR) is a cyclic heptapeptide toxin pro-
duced by several genera of cyanobacteria. The increased oc-
currence of cyanobacterial blooms emphasises the need to
investigate both the e¡ects of the toxin on humans and ani-
mals as well as mechanisms of bloom control and toxin re-
moval from human and animal water sources [1,2].
The development of primary liver cancer in China has been
linked to long-term chronic exposure to microcystin (MC)
[3,4]. People drinking pond or ditch water containing low
levels of MC had a higher mortality rate from hepatocellular
carcinoma than people drinking well water that did not con-
tain any MC [3^5]. In contrast to these observations is evi-
dence of MCLR-induced programmed cell death or apoptosis
both in vivo [6,7] and in vitro [8^10]. This apparent dualistic
response is characteristic of another well studied protein phos-
phatase (PP) inhibitor, okadaic acid (OA). This review at-
tempts to compare the processes of tumour promotion and
induction of apoptosis for MCLR and OA.
2. Biochemical cellular e¡ects of MCLR exposure
2.1. PP inhibition
MC is a potent inhibitor of the eukaryote serine/threonine
(Ser/Thr) protein phosphatases 1 and 2A (PP1 and PP2A) in
vitro [11,12] and in vivo [13] which suggests that the toxic
e¡ects of MC observed both in vivo and in vitro result
from the resultant so-called activation of protein kinases
[14]. MCLR inhibits PP1 and PP2A with an IC50 of about
0.1^1.0 nM [11,12]. Pre-incubation of PP2A with OA prevents
the subsequent binding of MCLR to the catalytic subunit of
the enzyme [12]. OA can be used to di¡erentiate between the
activity of these two PPs, with PP1 having an IC50 of 10 nM
and PP2A of 0.1 nM OA [12]. MCLR does not inhibit PP2C
[11,12] and has no e¡ect on the in vitro activity of two of the
cellular Ser/Thr protein kinases, protein kinase C (PKC) and
cAMP-dependent kinase (PKA) [11].
In vivo inhibition of PP by MC was shown in liver homo-
genates of mice exposed to toxin and was dose-dependent for
both MCYM (dose range 20^200 Wg/kg) and MCLR (dose
range 15^120 Wg/kg) [13]. Both PP1 and PP2A covalently
bind MCLR [6,15] at cysteine-273 for PP1 and cysteine-266
for PP2A [15,16].
2.2. E¡ects of MC on the cytoskeleton
The cellular cytoskeleton consists of three protein compo-
nents, namely microtubules, intermediate ¢laments and micro-
¢laments. Hyperphosphorylation of the intermediate ¢laments
is a consequence of exposure to OA [17]. MCLR at 1 WM
induced hyperphosphorylation of the major intermediate ¢la-
ment proteins keratin 8 and 18 [18] in a dose- and time-de-
pendent manner [19]. Similar results were found for the des-
moplakin proteins DPI and DPII, proving that the Ser/Thr
PP1 and PP2A are important regulators of the intermediate
¢lament proteins’ phosphorylation status [19]. The in vivo
protein kinases responsible for the hyperphosphorylation reg-
ulating K8 and K18 have not been identi¢ed but candidates
are PKC, PKA or the calcium/calmodulin-dependent kinase
(CaMKII) [20].
Increased phosphorylation of cytoplasmic dynein resulted
in impaired motor function accompanied by a reduction in
the recovery of endosomal/lysosomal membranes by microtu-
bules in hepatocytes exposed to both MCLR and OA [21].
The MCLR-induced changes in micro¢laments and microtu-
bules in primary rat hepatocytes occurred before lactate de-
hydrogenase (LDH) leakage with the authors suggesting that
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binding of MCLR directly to the cysteine residues found on
the tubulin subunits could have resulted in more free tubulin
in the cytoplasm, thereby reducing the stability of the tubulin
mRNA and a decrease in cellular tubulin [22].
2.3. Molecular mechanisms underlying the response to PP
inhibitors
The e¡ects of the PP inhibitors MC and OA on cellular
metabolism are confusing. Both are involved in tumour pro-
motion and yet are also involved in the con£icting response of
cell death by means of apoptosis. The cell cycle is regulated by
a delicate balance between phosphorylation and dephosphor-
ylation of key control proteins [20]. The speci¢c dephosphor-
ylation of Ser/Thr residues plays an essential role in control of
the cell, with more than 97% of protein phosphates occurring
at Ser/Thr residues [23]. Therefore, by inhibiting both PP1
and PP2A, MCLR and OA are able to interact with a variety
of molecular targets, resulting in an overall increase in phos-
phorylation of regulatory proteins. These e¡ects have been
chie£y investigated using OA, as this toxin is e¡ective at
very low concentrations on a wide variety of cells [24]. MC,
however, requires an active bile transport system to be taken
into hepatocytes [25], which is not found in immortalised he-
patocyte or non-hepatocyte cell lines [26].
2.3.1. E¡ects of PP inhibition on protein kinases. The tu-
mour-promoting activity of MC is likely to arise from its
ability to potently inhibit PP2A (Fig. 1) which regulates sev-
eral mitogen-activated protein kinases (MAPK) [27]. OA ac-
tivates a variety of protein kinases (see Rossini [24] for a
comprehensive review) possibly by activating the MAPK cas-
cade via tyrosine kinase-linked G protein receptors which
would in turn activate phospholipase C (PLC) as illustrated
in Fig. 1. Generation of diacylglycerol (DAG) by cleavage of
phosphatidylinositol 4,5-bisphosphate (PIP) would activate
PKC which in turn would trigger activation of the MAPK
cascade involving Raf-1, MEK, and ERK [20,24]. Two of
the major forms of MAPK, ERK1 and ERK2, are regulated
by the action of PP2A. Treatment of normal human and
mouse ¢broblasts with OA resulted in increased phosphoryla-
tion of the p42 MAPK, ERK2, within 60 min [28]. Another
MAPK, p38, is also phosphorylated in a cascade resembling
that of the ERKs and is thought to include some additional
kinase regulatory steps [20,24,27]. It is important to note that
the e¡ect of OA on MAPKs is dependent on cell type, with no
increase in ERK2 phosphorylation being observed in HeLa or
HTC cells exposed to OA [28].
The MAPKs in turn regulate transcription of genes re-
quired for cellular proliferation, such as the transcription ac-
tivator protein, c-Jun [20]. OA treatment of Jurkat cells in-
duced an increase in synthesis of nuclear factor UB enhancing
binding protein and transcription activator protein complex
[17]. An increase in transcription of the proto-oncogenes c-jun
and c-fos was also observed [17]. The activity of Jun-activat-
ing kinase (JNK), a PP2A-regulated enzyme [27], was induced
in human monocytic leukaemia cells upon exposure to OA
[29].
Fig. 1. The proposed scheme illustrating cellular events upon MCLR exposure. The MAPK pathway is usually activated by means of receptor
tyrosine kinases activated by G-linked receptors which activate the cleavage of PIP to DAG and IP3 by PLC. IP3 triggers the release of Ca2þ
from the endoplasmic reticulum (ER), but this does not occur for MCLR as MCLR inhibited vasopressin-induced Ca2þ release. DAG release
and increased Ca2þ are known to activate PKC activation of MAPKK which in turn activates MAPK. PKC was not found to play a role in
MCLR-induced kinase activation in vivo. PP2A regulates the phosphorylation of both MAPKK and MAPK so inhibition of this PP by
MCLR would allow for the continual activation of both these kinases. Once activated MAPK is translocated to the nucleus where it activates
transcription factors such as c-jun and c-fos, which initiate transcription of genes necessary for growth and di¡erentiation. The MAPK, ERK2,
is known to be activated by OA and is responsible for activating nuclear transcription factors, but this is unknown for MCLR (?). Increased
phosphorylation of p53 occurs in MCLR-exposed hepatocytes, however the e¡ect on p21WAF remains to be elucidated (?). MCLR induces the
formation of reactive oxygen species (ROS) which triggers mitochondrial permeability transition (MPT) prior to the release of Ca2þ from the
endoplasmic reticulum which activates CaMKII, phospholipase A2, cyclooxygenase and the calpains. ROS are known to activate the PP2A-
regulated kinase, JNK, which leads to increased c-jun activity, but the role of JNK in MCLR toxicology is not known (?). Cytochrome c re-
lease from the mitochondria after MPT usually results in activation of the caspase cascade, however the role of caspases in MCLR-induced ap-
optosis remains to be clari¢ed.
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PP2A negatively regulates several of the kinases involved in
the MAPK cascade, and its inhibition by chronic, low level
doses of MC could have severe regulatory e¡ects on cell cy-
cling [20]. It has been suggested that activation of MAPK may
inhibit apoptosis, thereby providing an underlying mechanism
for the tumour-promoting activity of the Ser/Thr PP inhibi-
tors resulting in increased cellular proliferation (Fig. 1) [20].
2.3.2. The e¡ect of PP inhibition on cellular proliferation.
The eukaryotic cell cycle has checkpoints between the four
phases G0/G1, S, G2 and M, to regulate accurate cell division,
the major control sites being found between G1/S and G2/M
phases. Cyclin-dependent kinases (CDKs) play an important
role in regulating the transition from one stage to the next,
and their activity is controlled by their state of phosphoryla-
tion/dephosphorylation and presence/absence of their regula-
tory cyclin protein. A CDK1 target late in the G1 and S
phases is retinoblastoma (Rb) protein. In its phosphorylated
state, Rb releases e2f transcription factor, which immediately
leads to increased mRNA synthesis of the genes required for
DNA replication [24]. Phosphorylation of Rb has also been
found to be decreased in OA-exposed cells which have been
serum-starved and then exposed to growth factors [17,24].
Contradicting results were obtained whereby increased phos-
phorylation of Rb was observed in ML-1 cells exposed to OA
[30]. OA treatment of quiescent hamster and human ¢bro-
blasts pushed 30^40% of cells from G0/G1 to S phase [31].
This increased proliferation was accompanied by an increase
in phosphorylation of Rb and MAPKs.
One can therefore conclude that OA can act as a stimulator
of proliferation either by increasing the phosphorylation of
proteins, such as Rb, or by preventing critical dephosphory-
lation of these proteins by PP2A. The e¡ect of MC exposure
on Rb phosphorylation has not been investigated.
OA exposure has resulted in increased expression of several
genes, the most critical being that of p21WAF1. This 21 kDa
protein acts as an inhibitor of cyclin D-, E- and A-dependent
kinases, thereby blocking the cell cycle in G1. This deregula-
tion of p21WAF1 has been observed in ¢broblasts and tumour
cells exposed to OA [24].
The protein, p53, is an important regulator of the cell cycle
and apoptosis. Increased phosphorylation of p53 halts cell
cycling by increasing transcription of p21WAF1. Its activity is
controlled by conformational changes resulting from phos-
phorylation/dephosphorylation, which is regulated by PP2A
and PP1, or inhibition of its degradation [23,24,32]. OA ex-
posure induced increased phosphorylation of p53 in ¢bro-
blasts [33]. The increase in phosphorylation was not accom-
panied by an increase of transcription of p53 and was found
to precede apoptosis in BALB/3T3 cells exposed to 500 nM
OA [34]. In its phosphorylated form, p53 has been found to
both increase and decrease transcription rates in OA-exposed
cells [35]. The OA-induced increase in phosphorylation of p53
was accompanied by an increase in its association with
p21WAF and increased levels of mRNA for p21WAF [35].
There was an overall increase in transcription of repair and
detoxi¢cation genes in the livers of rats exposed to a sublethal
dose of MCLR and killed after 3 or 6 h [36]. Increased phos-
phorylation of p53 was observed in the livers of rats exposed
to either a lethal (100 Wg/kg) or sublethal (45 Wg/kg) dose of
MCLR [23]. This is the ¢rst evidence of MCLR-induced e¡ect
on cell cycle control and supports the data obtained for OA
modulation of cell cycling. However, it is prudent to remem-
ber that MC and OA di¡er at least 10-fold in their inhibition
of PP1 which may result in potentially di¡erent e¡ects on
cellular biochemistry.
3. Apoptosis and oxidative stress
3.1. In vitro investigations
OA-treated hepatocytes clearly undergo apoptosis as evi-
denced by internucleosomal DNA fragmentation, bleb forma-
tion and packaging of cytoplasmic organelles [17,37]. The ¢rst
ever in vitro investigation into the toxic e¡ects of a MC ex-
tract on primary hepatocytes demonstrated the characteristic
apoptotic feature of cell membrane blebbing within 5 min of
exposure to the toxin [38]. Primary rat hepatocytes have been
used extensively to investigate the induction of oxidative stress
and apoptosis arising from exposure to MCLR and this is the
subject of a comprehensive review [10].
Exposure to MCLR extract resulted in increased lipid per-
oxidation, indicative of oxidative stress, in primary hepato-
cytes [39]. Increases in levels of reactive oxygen species
(ROS) preceded the onset of mitochondrial permeability tran-
sition (MPT) and initiation of apoptosis in hepatocytes ex-
posed to 1 WM MCLR [40]. Pre-exposure of hepatocytes to
the iron chelator deferoxamine or cyclosporin A, a speci¢c
inhibitor of MPT, prevented MPT and cell death, thereby
demonstrating the requirement of MPT in the MCLR-induced
apoptotic cascade [39,40]. Generation of ROS (determined by
changes in H2O2 and O32 concentrations) preceded the
MCLR-induced collapse of the cytoskeleton and subsequent
release of LDH in hepatocytes exposed to 1 WM MCLR in the
medium [41]. Addition of a superoxide dismutase mimic pre-
vented the collapse and LDH release, presumably by inacti-
vation of the ROS [41].
OA-induced apoptosis in hepatocytes and the human hep-
atoma cell line Hep3B was found to be caspase-dependent
[37]. Both DNA fragmentation and cleavage of poly(ADP-
ribose) polymerase (PARP) were clearly visible after 48 h
treatment with 50 nM OA [37]. Although cleavage of caspases
3/7, 2 and 9 was recorded, the exact mechanism of activation
of OA-induced caspase-dependent apoptosis is not known
[37,42]. Interestingly, no cleavage of caspase 8 was noted in
either study.
Ceramide is a cell-signaling molecule implicated in the con-
£icting processes of either cell di¡erentiation and growth in-
hibition or cellular proliferation [43]. It is known to interact
with at least four cellular targets, including the ceramide-acti-
vated PP1 [44]. Serine/arginine-rich proteins (SR) are sub-
strates of PP1 and known modulators of mRNA splicing.
Ceramide activation of PP1 resulted in dephosphorylation of
SR proteins [45]. More recently, it has been proposed that
ceramide-induced apoptosis results from the alternative splic-
ing of pre-mRNA for caspase 9 and BclXL mediated by PP1
[46]. This stage in the apoptotic pathway could conceivably be
inhibited by MC.
Cytochrome c release was induced in primary hepatocytes
exposed to 1 WM MCLR and addition of inhibitors of MPT
markedly reduced the release of cytochrome c into the cytosol
and signi¢cantly reduced the leakage of LDH from the hepa-
tocytes [47]. The release of cytochrome c did not surprisingly
activate caspase 9. Caspase 3 activities were reduced after
exposure to MCLR and no PARP cleavage was observed.
MCLR did, however, activate the calcium-activated cysteine
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proteinase calpain [47]. The authors suggested that the increase
in calpain activity resulted from MCLR-induced increase of
Ca2þ in the cytoplasm; however, the exact mechanism of
how MCLR a¡ects the intracellular Ca2þ homeostasis is not
yet known [10,47]. Increased activity of both milli- and micro-
calpain were observed in MCLR-exposed Caco2 [48] cells sug-
gesting that this mechanism extends to non-hepatic cells.
Apoptosis was induced in rat and salmon hepatocytes ex-
posed to either 1 WM MCLR or OA [49]. Addition of the
CaMKII inhibitor KN93 inhibited the development of apo-
ptosis in hepatocytes exposed to MCLR. Both MCLR (16
WM) and nodularin (5 WM), a toxic pentapeptide cyanotoxin
with PP inhibitory properties, induced apoptosis in primary
hepatocytes [50]. Nodularin-induced apoptosis was inhibited
by the addition of the general caspase inhibitor Z-VAD.fmk,
but was independent of Bcl-2 levels in rat leukaemia cells and
human breast carcinoma cells (MCF-7) treated with 250 or
500 WM toxin respectively [50].
MCLR-exposed hepatocytes exhibited an increase in overall
cellular protein phosphorylation, which correlated with an
increase in apoptogenic events within the cell [51]. The au-
thors assumed that there could only be increased protein
phosphorylation in cells exposed to a PP inhibitor if there
was increased kinase activity. The multifunctional CaMKII
is activated by intermolecular autophosphorylation at Thr286
in the presence of calcium and calmodulin. PP1 and PP2A are
able to reverse this autophosphorylation at Thr286, however
inhibition of these PPs by MCLR would lead to activated
CaMKII. Addition of the CaMKII-speci¢c inhibitors KN93
and KN5926 to MCLR-exposed hepatocytes completely in-
hibited the increase in protein phosphorylation and prevented
the apoptotic cascade seen in cells not treated with the inhib-
itor [51]. Inhibitors targeting casein kinase, cyclin-dependent
kinases and tyrosine kinases did not prevent apoptosis when
added to the medium with 0.4 WM MCLR. Microinjection of
inhibitors speci¢c for myosin light chain kinase and PKC
together with various MCLR concentrations into rat hepato-
cytes did not protect the cells from death [51].
Cells not able to actively take up MC have been shown to
undergo morphological changes indicative of apoptosis in re-
sponse to exposure to MC, albeit at concentrations consider-
ably higher than observed for primary rat hepatocytes
[8,9,52]. The protection o¡ered by CaMKII inhibitors was
shown to be e¡ective in non-hepatocyte cell lines: mouse
embryonic ¢broblasts (C3H C18 and Swiss 3T3), normal
rat kidney cells (NRK), human embryonic kidney cells
(HEK293), monkey kidney cells (COS-1) and rat promyelo-
cytic leukaemia cells (IPC-81) [51].
As previously mentioned, CaMKII kinase is activated by an
increase in Ca2þ in the cytosol. Inhibition of vasopressin-in-
duced receptor-mediated and G protein phosphoinositide
turnover occurred in rat hepatocytes exposed to 1 WM MC
[53]. MC also inhibited the inositol 1,4,5-triphosphate (IP3)
induction of angiotensin II and epinephrine. A consequence of
IP3 release is the increase of intracellular Ca2þ release from
the endoplasmic reticulum. An increase in cytosolic Ca2þ
alone is not su⁄cient to induce apoptosis, as activation of
CaMKII by the Ca2þ-elevating agent vasopressin did not re-
sult in apoptosis [51]. CaMK was also implicated in the in-
creased phosphorylation of the intermediate ¢lament K8 in
hepatocytes exposed to 10 WM MCLR, but did not a¡ect
the phosphorylation state of K18 [19].
Nobre et al. [54] found that MCLR impaired the renal
function of rats and these impairments could be antagonised
by dexamethasone and indometacin. A previous study found
that dexamethasone inhibited the release of arachidonic acid
induced by MCLR in rat hepatocytes [55]. It is also known
that MCLR induces cyclooxygenase via the release of arachi-
donic acid and that these events are related to the release of
calcium in the cell [54]. The PP inhibitor activity of MCLR
may lead to the activation of PKC which could in turn also
activate phospholipase A2 [54] ; however, as PKC does not
play a role in MCLR-induced cell death [51], phospholipase
A2 activation presumably arises from increased release of
Ca2þ in the cytoplasm. Phospholipase A2 activation is also
observed in OA-exposed hepatocytes [24]. Recent work sug-
gests a role for tumour necrosis factor K in MCLR-induced
activation of phospholipase A2 [56].
3.2. In vivo investigations
Mice given a lethal dose of MCLR (57.6^101.3 Wg/kg),
showed extensive bleeding in the centrilobular regions at
death [57]. Both the cytoplasm and nuclei of the centrilobular
hepatocytes surrounded by haemorrhaging stained strongly
for MCLR. Mice given a lower dose (57.6 and 69.1 Wg/kg)
were killed at 24 h. Sections of liver exhibited focal coagula-
tive necrosis, mainly in the midzonal areas extending towards
the central veins which did not stain for MCLR. Mice dosed
with sublethal toxin doses (20, 30 and 45 Wg/kg) and killed
after 7 days exhibited high levels of apoptotic cells in the
centrilobular and perinecrotic regions, some of which corre-
lated with positive immunostaining for MCLR. The authors
suggested a role for MCLR-induced apoptosis ; however, the
fact that no MCLR was found in the necrotic regions sug-
gested a role for damage due to ischaemia/hypoxia [57].
The role of oxidative stress in MC-induced toxicosis was
investigated in rats continually dosed with puri¢ed MCLR
at three di¡erent dose levels : low (16 Wg/kg), medium (32
Wg/kg) and high (48 Wg/kg) [7]. There were no signi¢cant
changes in liver weights, a clear indication of haemorrhage
induced by exposure to MCLR, between the control and ex-
perimental animals. High dose rats showed apoptosis in the
centrilobular areas, with fewer apoptotic cells visible in the
medium dose rats. Apoptotic cells were a rare occurrence in
the low dose rats. Levels of malondialdehyde, a by-product of
lipid peroxidation, were signi¢cantly raised in the medium and
high dose rats, with levels of malondialdehyde in low dose
level rats approaching those of the controls [7]. As lipid per-
oxidation is a good indicator of oxidative stress in cells, the
authors concluded that chronic exposure to sublethal doses of
MCLR resulted in oxidative stress and suggested that it may
play an important role in the chronic liver damage induced by
MCLR toxicosis at sublethal levels. Lipid-derived free radicals
were formed in the livers of rats treated with 50 Wg/kg MCLR
[58]. Repeated exposure of mice to a 75% LD50 dose of
MCLR resulted in an increase in malondialdehyde levels in
the liver [59]. An increase in lipid peroxidation levels was also
recorded in the livers of mice receiving a single sublethal dose
of MCLR [60]. The MCLR-induced increase in lipid peroxi-
dation preceded an increase in transcription and activity of
glutathione peroxidase in the liver.
Apoptosis was only detectable in the livers of mice 24 h
after a single sublethal dose of 45 Wg/kg MCLR [6]. No apo-
ptotic cells were visible in the livers of mice killed at 2, 4 and
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12 h. Mice killed after 2 h exhibited enlarged hepatocytes
accompanied by a loss in vacuolation, an indication of glyco-
gen depletion, which stained intensely in the cytoplasm for the
presence of MCLR thereby indicating a strong correlation
between the presence of the toxin in the cell and the altered
morphology. Mice exposed to four or seven doses of MCLR
showed extensive hepatocytomegaly, but again, only small
numbers of apoptotic cells were observed in both treatment
groups [6].
4. Tumorigenesis
Regular monitoring of formal water sources aims to reduce
exposure of individuals to the WHO level of MC of 1 Wg/l.
Studies in China, however, suggest that long-term chronic
exposure to much lower concentrations of toxin may pose a
far greater risk to people exposed on a regular basis to toxin
in their drinking water [3,5]. The elucidation of the process of
MCLR-induced tumorigenesis has been approached from sev-
eral directions.
4.1. In vitro tumorigenesis
The ability of MC to act as a tumour initiator would re-
quire it to induce damage at the DNA level in addition to
inhibiting the PPs to promote cellular proliferation. Baby
hamster kidney cells (BHK-21) and mouse embryo ¢broblast
(MEF) cells exposed to MC containing extract or pure MC
exhibited severe fragmentation of DNA at the higher dose
levels of 100 Wg/ml extract, and 1 and 2 Wg/ml MCLR [61].
The fragmentation was time-dependent with the most frag-
mentation observed after 3 h exposure to the toxins. OuaR
mutations, a measure of genotoxicity, were induced in a dose-
dependent manner in human Rsa cells exposed to 15 Wg/ml
MCLR with 170 OuaR mutants per 104 survivors [62]. Con-
trol cells had only one OauR cell per 104 survivors. MC-ex-
posed cells showed mutations at K-ras codon 12. A MC-con-
taining extract induced DNA damage in hepatocytes and
showed strong mutagenicity in the Ames test [63]. MCLR-
induced DNA strand breaks in the human hepatoma cell
line HepG2 occurred in a time- and dose-dependent manner
[64].
By far the most comprehensive in vitro investigation on
MCLR-induced increased cellular proliferation was done in
hepatocytes derived from C3H/HeJ mice [65]. Cells numbers
increased signi¢cantly after exposure to 1 nM MCLR for 18
and 42 h. This increase was not, however, accompanied by an
increase in total DNA levels or DNA synthesis, suggesting
that octaploid and tetraploid hepatocytes had undergone cell
division without a round of DNA replication. Hepatocytes
exposed to 3 nM MCLR increased slightly in cell number
after 18 and 42 h, whereas exposure at 10 nM reduced cell
numbers by 50% within 18 h. Repeated exposure of hepato-
cytes to MCLR at concentrations ranging from 10 to 100 pM
resulted in an increase in hepatocyte cell numbers as seen for a
single dose of 1 nM MCLR. OA was approximately 10-fold
more toxic than MCLR at 10 nM with DNA synthesis being
inhibited at all concentrations greater than 0.3 nM OA [65].
4.2. In vivo tumorigenesis
The obvious approach to investigate MCLR tumorigenesis
is to conduct long-term, oral dose studies in susceptible ani-
mals. Four of 71 mice receiving the highest concentration of
an extract of MC developed liver tumours, whereas only two
of the 223 mice receiving the lower dose developed any tu-
mours after a year [66].
The tumour promoter activity of OA was demonstrated
using a two-stage carcinogenesis model whereby an initiator
is ¢rst administered to the test animal prior to the potential
tumour promoter under investigation [17]. A topical epithelial
tumour initiator, dimethylbenzanthracene, was applied to the
skin of the backs of mice prior to repeated administration of
MCLR [67]. There were signi¢cantly bigger tumours on MC-
exposed mice than on the control mice after 52 days support-
ing the theory that MCLR was indeed a tumour promoter.
This was con¢rmed in rats dosed with levels of MCLR
below acute toxicity levels, after initially being primed with
the liver-speci¢c tumour initiator diethylnitrosamine (DEN)
[68]. Rats treated repeatedly with 10 Wg/kg, twice a week for
5 weeks, demonstrated increased numbers of placental gluta-
thione S-transferase (GST-P)-positive foci per square centi-
metre of liver tissue when compared to the lower dose group
and the control animals. The development of MCLR-induced
GST-P-positive liver tumour foci was found to be dose-depen-
dent [68].
In order to further investigate the duodenal and/or adeno-
carcinoma tumour-promoting activity of MC, mice were
dosed with N-methyl-N-nitrosourea, a tumour initiator, fol-
lowed by oral Microcystis toxin in their drinking water for
154 days [69]. No signi¢cant di¡erence in tumour formation
was recorded between the control and experimental groups
suggesting that MC is not a tumour promoter for duodenal
and/or adenocarcinomas [69]. Male C57BL/6J mice were
dosed with the tumour initiator azoxymethane and provided
with MC extract (equivalent to a daily dose of 382 and 693
Wg/kg) in their drinking water to investigate the potential of
MCLR to promote tumours in the gastrointestinal tract
[70]. The size of aberrant crypt foci, indicative of the devel-
opment of colon cancer, was signi¢cantly raised in the
colons of MCLR-exposed animals, suggesting an increased
risk for the development of bowel cancer upon exposure to
MC [70].
Exposure to MCLR coupled with a demonstrated tumour
initiator such as a£atoxin B1 may result in an increased rate of
liver cancer [71]. A£atoxin B1 did not, however, act synergis-
tically with MCLR in increasing the numbers of GST-P-pos-
itive foci in the livers of DEN-initiated rats exposed to both
agents. A synergistic e¡ect was observed in rats initiated with
a£atoxin B1 and subsequently exposed to MCLR at 1 or 10
Wg/kg, supporting the role of MCLR as a tumour promoter
[71].
The ability of MC to act as a tumour initiator was also
investigated. Neoplastic nodules were identi¢ed in the livers
of ICR mice injected with 100 doses of MCLR (20 Wg/kg) for
28 weeks [72]. Orally administered toxin (80 Wg/kg MC, 100
times for 28 weeks) did not induce the formation of any liver
damage or nodule formation.
MCLR induced random DNA fragmentation in the livers
of mice injected with MCLR, which correlated to increased
hepatocellular damage as measured by release of LDH, alka-
line phosphatase and Q-glutamyl transferase [73]. MCLR-in-
duced DNA damage was time- and dose-dependent [61].
MCLR targeting of hepatocyte nuclei was demonstrated after
2 and 4 h in the livers of mice having received a single dose of
45 Wg/kg [6]. These studies suggested that MCLR may exert
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an e¡ect at the DNA level which could possibly lead to in-
creased cellular proliferation.
5. Discussion
It is apparent after reading the current literature that there
is no clear picture of the exact mechanism of toxicity of MC
in the liver. That it inhibits PP1 and PP2A is a crucial pivot
with far-reaching consequences in cellular biochemistry, most
noticeably the ‘activation’ of cellular kinases. Whether the
hepatocyte undergoes apoptosis or increased cellular prolifer-
ation appears to be dependent on the e¡ective concentration
of toxin to which it is exposed as demonstrated in vitro [65].
Generation of ROS is also an important consequence of MC
exposure [41] with far-reaching e¡ects on cellular activities
including activation of MPT [74], calpain [47], CaMKII [51]
and phospholipase A2 [54] activities. In addition, oxidative
stress is a known stimulus of MAPK and H2O2 can induce
the activity of JNK [75]. Either or both of these mechanisms
could induce hepatic damage leading to necrosis/apoptosis
and/or increased cellular proliferation [10,20]. The extent of
injury in vivo is in turn dependent on the level of exposure to
the toxin [57], e⁄ciency of uptake [25] and the detoxi¢cation
process within the liver to remove both MC and MCLR-in-
duced ROS [10]. It is di⁄cult to compile a complete overview
of the toxic e¡ects of MC on the liver as some investigators
make use of puri¢ed toxins while others choose to use the
more realistic model of a MC extract. An additional compli-
cation is comparing results obtained from studies undertaken
in vitro which may not necessarily apply to the in vivo sce-
nario.
To summarise, the induction of apoptosis in vitro in
MCLR-exposed hepatocytes is closely linked to the generation
of ROS, MPT, Ca2þ release into the cytoplasm and inhibition
of PP1 and PP2A. The role of caspases and proteases in
MCLR-induced programmed cell death in vivo is an active
area of research. In vitro exposure to MCLR induces in-
creased lipid peroxidation in the liver, indicating increased
Fig. 2. Simpli¢ed view of the molecular basis underlying the dualistic responses triggered in cells exposed to the PP inhibitor MCLR. Modi¢ed
from Rossini [24] for MCLR.
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oxidative stress; however, the causal link to apoptosis is not
as clear as in vitro studies suggest. Apoptosis occurs after a
delayed period in animals given a sublethal dose of toxin and
in patches within the liver tissue. The occurrence of apoptotic
cells on the periphery of necrotic areas suggests a role for
ischaemia in the development of apoptosis in MCLR-treated
animals. The di¡erence in the induction of apoptosis between
in vivo and in vitro studies may be attributed to single hepa-
tocytes being exposed to varying levels of toxin, the level de-
pendent on two processes: uptake by the bile transport system
and clearance by the glutathione detoxi¢cation pathway.
That MC targets the nucleus [76] and appears to damage
the DNA [62,73] may in£uence expression of DNA in a MC-
exposed hepatocyte. In addition to this, inhibition of PPs
would in£uence activation of transcription factors such as
c-fos and c-jun, as demonstrated for OA (Fig. 1).
In vitro studies have clearly illustrated the ability of MCLR
to induce DNA damage in exposed cells. They have also more
clearly di¡erentiated between cell death and proliferation in-
duced in mouse hepatocytes exposed to varying levels of
MCLR. Low doses of MCLR (9 1 nM) appear to cause an
increase in cell numbers while higher doses of toxin (v 10
nM) reduce cell viability [65]. In vivo studies indicate a clear
role for MCLR to act as a tumour promoter at dose levels in
the range of 1^10 Wg/kg i.p. or 382^693 Wg/kg orally, being
associated with the development of liver, skin and possibly
colon cancer.
The fact that apoptosis is generally only reported at high
doses of MC both in vivo and in vitro and increased cellular
proliferation is observed at lower concentrations supports the
dualistic response to this toxin as summarised in Fig. 2. It is
accepted that apoptosis and proliferation often occur simul-
taneously within the same cell in the liver [51,75]. It is possible
that the observed tumour promotion observed for MCLR
could be due to MAPK signaling which stimulates cellular
proliferation while inhibiting apoptosis. There is also very
little evidence to suggest that one of the direct causes of he-
patic injury resulting from chronic low level MC exposure in
vivo is the result of apoptosis. It is more likely that the apo-
ptosis observed at higher dose levels is the result of hypoxia
resulting from obstruction of blood £ow to the hepatic tissues.
Apoptosis has not been noted at the low levels of toxin used
to induce tumours or cellular proliferation either in vivo or in
vitro. It is clear that more information is required to further
elucidate the toxic e¡ects of MC on the liver of exposed in-
dividuals, be it acute or long-term chronic exposure.
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